Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash from Operations for 7 consecutive years, with 17788000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 62.68% to 17788000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 128336000.0 through Dec 2025, up 17.47% year-over-year, with the annual reading at 128336000.0 for FY2025, 17.47% up from the prior year.
  • Cash from Operations for Q4 2025 was 17788000.0 at Pliant Therapeutics, up from 21081000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 13665000.0 in Q1 2021, with the low at 48864000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 28513700.0, with a median of 24930500.0 recorded in 2023.
  • The sharpest move saw Cash from Operations tumbled 349.65% in 2021, then skyrocketed 62.68% in 2025.
  • Over 5 years, Cash from Operations stood at 19865000.0 in 2021, then tumbled by 57.26% to 31239000.0 in 2022, then rose by 19.65% to 25102000.0 in 2023, then tumbled by 89.87% to 47662000.0 in 2024, then surged by 62.68% to 17788000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 17788000.0, 21081000.0, and 40603000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.